Stay updated on Immunotherapy Combinations in Gastric Cancers Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy Combinations in Gastric Cancers Clinical Trial page.

Latest updates to the Immunotherapy Combinations in Gastric Cancers Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision added: v3.4.2. The government funding operating status notice and the prior revision note (v3.4.1) were removed.SummaryDifference0.3%

- Check21 days agoChange DetectedNew site-wide notice informs users about a lapse in government funding and directs to cc.nih.gov for updates; the page also shows a revision update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedThe page now includes a 'Show glossary' option and updates several metadata labels, including 'Last Update Submitted that Met QC Criteria', 'Last Update Posted', 'No FEAR Act Data', and the revision tag 'Revision: v3.4.0' to replace earlier labels/versions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check57 days agoChange DetectedA new publication citation has been added under Publications: Sun JM et al., MORPHEUS-EC in Lancet Oncology 2026. This update does not change the study design, eligibility criteria, or reported outcomes.SummaryDifference0.0%

- Check64 days agoChange DetectedThe Locations section now includes Navarre and other regional locations, with some location subsections added or removed. The footer shows Last Update Posted (Estimated) and Revision: v3.3.3.SummaryDifference0.6%

Stay in the know with updates to Immunotherapy Combinations in Gastric Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy Combinations in Gastric Cancers Clinical Trial page.